JPS6359464B2 - - Google Patents
Info
- Publication number
- JPS6359464B2 JPS6359464B2 JP56092639A JP9263981A JPS6359464B2 JP S6359464 B2 JPS6359464 B2 JP S6359464B2 JP 56092639 A JP56092639 A JP 56092639A JP 9263981 A JP9263981 A JP 9263981A JP S6359464 B2 JPS6359464 B2 JP S6359464B2
- Authority
- JP
- Japan
- Prior art keywords
- monomer
- polymerizable
- weight
- hemoglobin
- polymerizable monomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000178 monomer Substances 0.000 claims description 47
- 108010054147 Hemoglobins Proteins 0.000 claims description 18
- 102000001554 Hemoglobins Human genes 0.000 claims description 18
- 230000001925 catabolic effect Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 230000005526 G1 to G0 transition Effects 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- 238000004811 liquid chromatography Methods 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 description 10
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 238000012856 packing Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000010828 elution Methods 0.000 description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 3
- HVVWZTWDBSEWIH-UHFFFAOYSA-N [2-(hydroxymethyl)-3-prop-2-enoyloxy-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(COC(=O)C=C)COC(=O)C=C HVVWZTWDBSEWIH-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007334 copolymerization reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000010557 suspension polymerization reaction Methods 0.000 description 3
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 2
- LTHJXDSHSVNJKG-UHFFFAOYSA-N 2-[2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOCCOC(=O)C(C)=C LTHJXDSHSVNJKG-UHFFFAOYSA-N 0.000 description 2
- 108010044267 Abnormal Hemoglobins Proteins 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 238000012662 bulk polymerization Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108010036302 hemoglobin AS Proteins 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- ZCHASXWZMYCGQR-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propane-1,3-diol;prop-2-enoic acid Chemical compound OC(=O)C=C.OC(=O)C=C.OCC(CO)(CO)CO ZCHASXWZMYCGQR-UHFFFAOYSA-N 0.000 description 1
- SJIXRGNQPBQWMK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-methylprop-2-enoate Chemical compound CCN(CC)CCOC(=O)C(C)=C SJIXRGNQPBQWMK-UHFFFAOYSA-N 0.000 description 1
- HLGNMOUJXWELKK-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC(=O)C(C)=C HLGNMOUJXWELKK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- JUDXBRVLWDGRBC-UHFFFAOYSA-N [2-(hydroxymethyl)-3-(2-methylprop-2-enoyloxy)-2-(2-methylprop-2-enoyloxymethyl)propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(CO)(COC(=O)C(C)=C)COC(=O)C(C)=C JUDXBRVLWDGRBC-UHFFFAOYSA-N 0.000 description 1
- SWHLOXLFJPTYTL-UHFFFAOYSA-N [2-methyl-3-(2-methylprop-2-enoyloxy)-2-(2-methylprop-2-enoyloxymethyl)propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(C)(COC(=O)C(C)=C)COC(=O)C(C)=C SWHLOXLFJPTYTL-UHFFFAOYSA-N 0.000 description 1
- HSZUHSXXAOWGQY-UHFFFAOYSA-N [2-methyl-3-prop-2-enoyloxy-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(C)(COC(=O)C=C)COC(=O)C=C HSZUHSXXAOWGQY-UHFFFAOYSA-N 0.000 description 1
- MPIAGWXWVAHQBB-UHFFFAOYSA-N [3-prop-2-enoyloxy-2-[[3-prop-2-enoyloxy-2,2-bis(prop-2-enoyloxymethyl)propoxy]methyl]-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(COC(=O)C=C)(COC(=O)C=C)COCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C MPIAGWXWVAHQBB-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 108010015562 acetylated hemoglobin Proteins 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005650 polypropylene glycol diacrylate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Description
【発明の詳細な説明】
本発明は血液中のヘモグロビンとくに異化ヘモ
グロビンを診断等のために分離定量する方法に関
するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for separating and quantifying hemoglobin in blood, particularly catabolic hemoglobin, for purposes such as diagnosis.
成人のヘモグロビン(以下Hbと略す)は分子
量約68000の蛋白質で、4個のヘムが1個のグロ
ビン蛋白に結合した形で存在している。ところが
アルカリ性のPH(PH8.6)の条件下で正常ヒトHb
を電気泳動させると90〜95%を占めるHb、すな
わちHbA0の他に、該HbA0よりも移動度が少し
遅れてHbF及びHbA1cが、さらに遅れてHbA1a、
HbA1b等が分離され、これらの存在が認められ
ている。さらに、より精密な電気泳動試験等の結
果から、HbA1d、HbA1e等の存在も確認されて
いる。これら異常ヘモグロビンは正常ヘモグロビ
ン(HbA0)に比して、蛋白の一次構造が違つて
いるものか或いはHbA0に糖が化合しているもの
等である。これらの異化ヘモグロビンの分離定量
は種々の病気の病態指標として重要であることが
分つており、例えばHbA1cの増減のチエツクは
糖尿病の治療に欠かせない。又、HbA2と称され
る成分はHbFと同様に遺伝性のものであり、さ
らにアセチル化ヘモグロビン(Ac、Hb)と称さ
れる異常ヘモグロビンはアセチル基を有する薬剤
例えばアスピリン等の服用により生成することが
判明してきており、これらの異化ヘモグロビンの
分離定量は医学的な見地からしてますます重要性
の度合が高まつている。 Adult hemoglobin (hereinafter abbreviated as Hb) is a protein with a molecular weight of approximately 68,000, and exists in the form of four hemes bound to one globin protein. However, under alkaline pH (PH8.6) conditions, normal human Hb
When electrophoresed, in addition to Hb, which accounts for 90 to 95%, that is, HbA 0 , there are HbF and HbA 1 c, whose mobility is slightly slower than that of HbA 0 , and HbA 1 a, which is further delayed.
HbA 1 b, etc. have been isolated and their existence has been recognized. Furthermore, the presence of HbA 1 d, HbA 1 e, etc. has also been confirmed from the results of more precise electrophoresis tests. These abnormal hemoglobins have a different primary protein structure compared to normal hemoglobin (HbA 0 ), or have sugars attached to HbA 0 . It has been found that the separation and quantification of these catabolic hemoglobins is important as a pathological indicator for various diseases; for example, checking for increases and decreases in HbA 1c is essential for the treatment of diabetes. Also, the component called HbA 2 is hereditary like HbF, and abnormal hemoglobin called acetylated hemoglobin (Ac, Hb) is produced by taking drugs with acetyl groups, such as aspirin. It has become clear that the separation and quantification of these catabolic hemoglobins is becoming increasingly important from a medical standpoint.
しかしながら現在までに、上記の様な異化ヘモ
グロビンを短時間で精度よく分離、定量すること
の出来る方法は提案されていなかつた。 However, up to now, no method has been proposed that can accurately separate and quantify catabolic hemoglobin as described above.
本発明は上記の如き現状にかんがみ、異化ヘモ
グロビンを糖度よくしかも短時間に分離、定量す
ることの出来る方法を提供することを目的として
なされたものであり、その要旨は、分子中に1個
の重合性2重結合と1個以上のアミノ基を有する
重合性モノマー(A)5〜90重量%、分子中に2個以
上の重合性2重結合を有しかつ疎水性パラメータ
ーが2,3以下の架橋重合性モノマー(B)10〜95重
量%、分子中に1個の重合性2重結合を有し疎水
性パラメーターが2.3以下にして上記重合性モノ
マー(A)とは異なるモノマー(C)0〜85重量%からな
るモノマー混合物が共重合されてなる親水性イオ
ン交換体を固定相とする液体クロマトグラフイー
によつて行われることを特徴とする異化ヘモグロ
ビンの分離方法に存する。 In view of the above-mentioned current situation, the present invention has been made for the purpose of providing a method for separating and quantifying catabolic hemoglobin with high sugar content and in a short time. 5 to 90% by weight of a polymerizable monomer (A) having a polymerizable double bond and one or more amino groups, having two or more polymerizable double bonds in the molecule and a hydrophobic parameter of 2.3 or less 10 to 95% by weight of a crosslinking polymerizable monomer (B), a monomer (C) having one polymerizable double bond in the molecule and having a hydrophobic parameter of 2.3 or less and different from the above polymerizable monomer (A). A method for separating catabolic hemoglobin, characterized in that it is carried out by liquid chromatography using as a stationary phase a hydrophilic ion exchanger copolymerized with a monomer mixture of 0 to 85% by weight.
本発明において特定の組成のモノマー混合物が
共重合されてなる親水性イオン交換体が、液体ク
ロマトグラフイーの固定相として用いられるので
ある。そして上記共重合されたイオン交換体を固
定相すなわち充填剤として用いるには、例えば共
重合により得られた共重合体粒子を粒径を揃える
等してそのまゝ充填剤として用いてもよく、バル
ク重合の場合は共重合体を粉砕したものを粒径を
揃えて用いてもよく、又はガラス球等の適宜な芯
材の表面に上記共重合体を適宜な方法でコーテイ
ングしたものを用いてもよい。 In the present invention, a hydrophilic ion exchanger formed by copolymerizing a monomer mixture with a specific composition is used as a stationary phase in liquid chromatography. In order to use the above-mentioned copolymerized ion exchanger as a stationary phase, that is, a filler, for example, the copolymer particles obtained by copolymerization may be made to have the same particle size and used as they are as a filler. In the case of bulk polymerization, a pulverized copolymer may be used with uniform particle size, or the surface of an appropriate core material such as a glass bulb may be coated with the above copolymer by an appropriate method. Good too.
しかして本発明充填剤を構成する共重合体は、
分子中に1個の重合性2重結合と1個以上のアミ
ノ基を有するを重合性モノマー(A)が5〜90重量
%、分子中に2個以上の重合性2重結合を有しか
つ疎水性パラメーターが2.3以下の架橋の重合性
モノマー(B)が10〜95重量%、分子中に1個の重合
性2重結合を有し疎水性パラメーターが2.3以下
にして上記重合性モノマー(A)とは異なるモノマー
(C)が0〜85重量%からなるモノマー混合物が共重
合されたものであり、この共重合には懸濁重合、
エマルジヨン重合、溶液重合、バルク重合等の従
来において行われている重合法が採用可能である
が、重合体粒子をそのまゝ充填剤として用いるこ
とが出来る点で懸濁重合法が好適である。又、懸
濁重合の際に、モノマーは溶解するが重合体を溶
解しない有機溶剤を少量加えておけば生成した共
重合体粒子は多孔質のものとなり、移動相との接
触面積が増大した充填剤が得られる。 However, the copolymer constituting the filler of the present invention is
5 to 90% by weight of the polymerizable monomer (A) having one polymerizable double bond and one or more amino groups in the molecule, and two or more polymerizable double bonds in the molecule and The crosslinked polymerizable monomer (B) with a hydrophobicity parameter of 2.3 or less is 10 to 95% by weight, and the above polymerizable monomer (A) has one polymerizable double bond in the molecule and has a hydrophobicity parameter of 2.3 or less. ) different monomer from
A monomer mixture containing (C) from 0 to 85% by weight is copolymerized, and this copolymerization includes suspension polymerization,
Conventional polymerization methods such as emulsion polymerization, solution polymerization, and bulk polymerization can be employed, but suspension polymerization is preferred because the polymer particles can be used as they are as a filler. Additionally, if a small amount of an organic solvent is added during suspension polymerization, which dissolves the monomer but does not dissolve the polymer, the resulting copolymer particles will become porous, resulting in a packing that increases the contact area with the mobile phase. agent is obtained.
ここで疎水性パラメーターとは或る化合物のオ
クチルアルコール水系への溶解度比の対数であ
り、その化合物特有の値である。そして該パラメ
ーターは実験によつても求められるが、分子中の
各フラグメントの寄与(疎水性フラグメント定
数)が計算によつて求められることが出来、これ
らの総和としてその化合物の疎水性パラメーター
値が算出できる。 Here, the hydrophobic parameter is the logarithm of the solubility ratio of a certain compound in an aqueous octyl alcohol system, and is a value specific to that compound. Although this parameter can be determined by experiment, the contribution of each fragment in the molecule (hydrophobic fragment constant) can be determined by calculation, and the hydrophobic parameter value of the compound is calculated as the sum of these. can.
疎水性パラメーター値の計算法については、
R.F.Rekker著「The Hydrophobic Fragmental
Constant」(Elsevier Scientific Publishing
Co.1977年発行)の第3章に述べられており、本
発明におけるパラメーター値はこの計算法に基づ
いている。 For information on how to calculate hydrophobicity parameter values, see
“The Hydrophobic Fragmental” by RFRekker
"Constant" (Elsevier Scientific Publishing)
Co., Ltd. (published in 1977), Chapter 3, and the parameter values in the present invention are based on this calculation method.
次に本発明において好適に用いられる重合性モ
ノマー(A)の例としてはメタクリル酸ジメチルアミ
ノエチル、メタクリル酸ジエチルアミノエチル等
が挙げられ、疎水性パラメーターが2.3以下のも
のが好適に用いられる。 Next, examples of the polymerizable monomer (A) preferably used in the present invention include dimethylaminoethyl methacrylate, diethylaminoethyl methacrylate, etc., and those having a hydrophobic parameter of 2.3 or less are preferably used.
又、本発明に用いられる架橋重合性モノマー(B)
の例としてはテトラメチロールメタントリアクリ
レート(疎水性パラメーター=−0.73、以下括弧
内はパラメーター値を示す。)、テトラメチロール
メタントリメタクリレート(0.59)、テトラメチ
ロールメタンジアクリレート(−1.70)、テトラ
メチロールメタンジメタクリレート(0.82)、テ
トラメチロールメタンテトラアクリレート
(0.24)、テトラメチロールメタンテトラメタクリ
レート(0.20)、トリメチロールエタントリアク
リレート(0.88)、トリメチロールエタントリメ
タクリレート(2.20)、ジペンタエリスリトール
ヘキサアクリレート(−0.09)等が挙げられ、そ
の他テトラエチレングリコールジメタクリレート
(−0.30)などのポリエチレングライコールジア
クリレート(又はメタクリレート)やポリプロピ
レングライコールジアクリレート(又はメタクリ
レート)等のアルキレングライコールジアクリレ
ート(又はメタクリレート)も使用出来る。又、
前記モノマー(A)とは異なるモノマー(C)は本発明に
おいて必要に応じて85重量%の量的範囲まで用い
ることが出来るのであるが、該モノマー(C)として
はNN―ジメチルメタアクリルアミド(−0.88)、
2―ヒドロキシエチルメタアクリレート(−
0.41)、グリシジルメタアクリレート(−0.48)
などが好適に用いられ、その他NN―ジメチルア
クリルアミド、2―ヒドロキシエチルアクリレー
ト、グリシジルアクリレートなども使用出来る。 Moreover, the crosslinking polymerizable monomer (B) used in the present invention
Examples include tetramethylolmethane triacrylate (hydrophobicity parameter = -0.73, below the parameter values are shown in parentheses), tetramethylolmethane trimethacrylate (0.59), tetramethylolmethane diacrylate (-1.70), and tetramethylolmethane. Dimethacrylate (0.82), Tetramethylolmethanetetraacrylate (0.24), Tetramethylolmethanetetramethacrylate (0.20), Trimethylolethane triacrylate (0.88), Trimethylolethane trimethacrylate (2.20), Dipentaerythritol hexaacrylate (-0.09) ), and alkylene glycol diacrylates (or methacrylates) such as polyethylene glycol diacrylate (or methacrylate) such as tetraethylene glycol dimethacrylate (-0.30) and polypropylene glycol diacrylate (or methacrylate) are also used. I can do it. or,
A monomer (C) different from the monomer (A) can be used in the present invention up to a quantitative range of 85% by weight if necessary. 0.88),
2-Hydroxyethyl methacrylate (-
0.41), glycidyl methacrylate (-0.48)
NN-dimethylacrylamide, 2-hydroxyethyl acrylate, glycidyl acrylate, etc. can also be used.
本発明においては上述の如く、重合性モノマー
(A)5〜90重量%、架橋重合性モノマー(B)10〜95重
量%からなるモノマー混合物若しくは必要に応じ
て前記モノマー(C)が85重量%まで加えられたモノ
マー混合物が共重合されるのであるが、得られた
共重合体はアミノ基を有する重合性モノマー(A)が
分子中に存在することによりそれ自体イオン交換
作用を示すイオン交換体となる。そしてモノマー
混合物において、アミノ基を有する1官能性のモ
ノマー(A)が少なすぎるとイオン交換能が低下する
のでモノマー(A)は5重量%以上が必要とされるの
であり、又、2個以上の重合性2重結合を有する
架橋重合性モノマー(B)の量が少なすぎると共重合
体中の架橋結合の密度が減じ、とくに高速液体ク
ロマトグラフ用充填剤として用いられた際、高圧
に対坑するための機械的強度に問題が生じるので
該モノマー(B)は10重量%以上が必要とされるので
ある。又、前記重合性モノマー(A)以外の重合性2
重結合を有するモノマー(C)は、重合性モノマー(A)
及び架橋重合性モノマー(B)の使用割合が必要量よ
り少くならない範囲で混合モノマー中に含まれる
ことが出来る。 In the present invention, as mentioned above, the polymerizable monomer
A monomer mixture consisting of (A) 5 to 90% by weight and a crosslinking polymerizable monomer (B) 10 to 95% by weight, or a monomer mixture in which the above monomer (C) is added up to 85% by weight as necessary, is copolymerized. However, the resulting copolymer itself becomes an ion exchanger exhibiting ion exchange action due to the presence of the polymerizable monomer (A) having an amino group in the molecule. In the monomer mixture, if there is too little monofunctional monomer (A) having an amino group, the ion exchange ability will decrease, so the monomer (A) needs to be at least 5% by weight, and it is also necessary to have at least 2 monomers (A). If the amount of the cross-linked polymerizable monomer (B) having a polymerizable double bond is too small, the density of the cross-linked bonds in the copolymer will decrease, making it difficult to withstand high pressure, especially when used as a packing material for high-performance liquid chromatography. Since a problem arises in mechanical strength for drilling, the monomer (B) is required to be in an amount of 10% by weight or more. In addition, polymerizable monomer 2 other than the polymerizable monomer (A)
The monomer (C) having a heavy bond is a polymerizable monomer (A)
and the crosslinking polymerizable monomer (B) can be included in the mixed monomer in such a range that the proportion used does not become less than the required amount.
本発明に用いられる親水性イオン交換体を共重
合により生成するモノマー混合物中に含まれるモ
ノマー(B),(C)は疎水性パラメーターが2.3以下と
なされるのであるが、これは、上記モノマー混合
物が共重合されたイオン交換体からなる充填剤が
異化ヘモグロビンの分析においてすぐれた分離能
を示すという本発明の知見にもとずくものであ
り、例えば従来からイオン交換体を製造するため
に架橋重合性モノマーとして常用されて来たジビ
ニルベンゼンは疎水性パラメーターが3.8と高い
ので、これが共重合成分として含まれるイオン交
換体を充填剤として用いても本発明の効果を奏し
得ないのである。 The monomers (B) and (C) contained in the monomer mixture produced by copolymerizing the hydrophilic ion exchanger used in the present invention have a hydrophobicity parameter of 2.3 or less; This is based on the knowledge of the present invention that a packing material made of an ion exchanger copolymerized with Since divinylbenzene, which has been commonly used as a monomer, has a high hydrophobicity parameter of 3.8, the effects of the present invention cannot be achieved even if an ion exchanger containing divinylbenzene as a copolymerization component is used as a filler.
又、前記重合性モノマー(A)、架橋重合性モノマ
ー(B)及び必要に応じて加えられるモノマー(C)の疎
水性パラメーターが0以下かマイナス側にあるの
が本発明における分析時に分析物質の充填剤への
吸着を防止する点で好ましい。 In addition, the hydrophobicity parameters of the polymerizable monomer (A), the cross-linking polymerizable monomer (B), and the monomer (C) added as necessary are 0 or less or on the negative side when analyzing the substance to be analyzed in the present invention. This is preferable in terms of preventing adsorption to the filler.
上記親水性イオン交換体は常法によりカラムに
充填されて、液体クロマトグラフによる本発明の
分離に用いられるのであり、その際にはイオン交
換機構にもとずく分析挙動を示す。 The above-mentioned hydrophilic ion exchanger is packed into a column by a conventional method and used for the separation of the present invention by liquid chromatography, and exhibits analytical behavior based on an ion exchange mechanism.
本発明による分離は、上記親水性イオン交換体
が充填されたカラムを液体クロマトグラフ好まし
くは高速液体クロマトグラフに接続し、それ以後
は液体クロマトグラフによる分離、定量の手法に
従つて試料である血液をクロマトグラフに注入
し、溶離液を流す等の操作により行うことが出来
る。分離の対象となる異化ヘモグロビンの種類や
使用するカラム充填剤の種類によつて最適な溶離
条件が決定さるべきであるが、一般に溶離液とし
てPH5.0〜10.0、イオン強度0.01の水溶液が用いら
れるのが好ましく、又、分離操作中にPHやイオン
強度を変化させる手法によつて種々の異化ヘモグ
ロビンを良好に分離、定量することが出来る。
又、検出は波長415nmの可視光を用いて行うのが
好ましい。 In the separation according to the present invention, the column filled with the above-mentioned hydrophilic ion exchanger is connected to a liquid chromatograph, preferably a high-performance liquid chromatograph. This can be done by injecting into a chromatograph and flowing the eluent. The optimal elution conditions should be determined depending on the type of catabolic hemoglobin to be separated and the type of column packing material used, but generally an aqueous solution with a pH of 5.0 to 10.0 and an ionic strength of 0.01 is used as the eluent. Moreover, various catabolic hemoglobins can be well separated and quantified by changing the pH and ionic strength during the separation operation.
Further, detection is preferably performed using visible light with a wavelength of 415 nm.
又、異化ヘモグロビンの溶出順序は一般に殆ん
ど変動しないが、溶離操作において溶離条件を変
化させることによつて、特定の異化ヘモグロビン
を良好なクロマトグラフピークとして出現させ、
他の異化ヘモグロビンや正常ヘモグロビンは分離
が良好でないまとまつたピークとして出現させて
目的とする異化ヘモグロビンの定量を短時間で効
果的に行うことも可能である。 In addition, the elution order of catabolic hemoglobin generally does not change much, but by changing the elution conditions during the elution operation, specific catabolic hemoglobin can be made to appear as a good chromatographic peak,
It is also possible to make other catabolic hemoglobins and normal hemoglobin appear as clustered peaks that are not well separated, so that the target catabolic hemoglobin can be quantified effectively in a short time.
本発明は上述の通りの異化ヘモグロビンの分離
法であり、とくに特定組成のモノマー混合物が共
重合されてなる親水性イオン交換体が固定相とし
て用いられ、該固定相は分離性能と共に強度的に
もすぐれているので高速液体クロマトグラフ用充
填剤として用いることが可能であり、本発明によ
れば異化ヘモグロビンを精度よくしかも短時間に
分離、定量することが出来るというすぐれた効果
を奏するのである。 The present invention is a method for separating catabolic hemoglobin as described above, in which a hydrophilic ion exchanger copolymerized with a monomer mixture having a specific composition is used as a stationary phase, and the stationary phase has both separation performance and strength. Because of its excellent properties, it can be used as a packing material for high performance liquid chromatography, and the present invention has the excellent effect of allowing catabolic hemoglobin to be separated and quantified with high accuracy and in a short time.
以下本発明の実施例について説明する。 Examples of the present invention will be described below.
実施例 1
冷却機、撹拌機、温度計および滴下ロートの設
置された2のセパラブルフラスコに4重量%の
ポリビニルアルコール水溶液400ml、テトラエチ
レングリコールジメタクリレート)40g、テトラ
メチロールメタントリアクリレート10g、ジエチ
ルアミノエチルメタクリレート50g、トルエン40
gおよびベンゾイルパーオキサイド1.5gよりな
る混合液を供給した。次に400rpmの撹拌速度で
撹拌しながら80℃に昇温し10時間反応を行つて冷
却した。冷却後重合生成を母液分離した後、熱水
およびアセトンで洗浄して粒子径が5〜20ミクロ
ンの球状ポリマーを得た。そのうち微粒子および
粗粒子を取除いて得られた8〜12ミクロンの粒子
を80mlのイオン交換水に分散し、ステンレスカラ
ム(直径7.9mm、長さ30cm)に高圧定流量ポンプ
により上記イオン交換水を1.6ml/分の速度で圧
送することにより充填した。Example 1 Into two separable flasks equipped with a cooler, a stirrer, a thermometer, and a dropping funnel, 400 ml of a 4% by weight aqueous polyvinyl alcohol solution, 40 g of tetraethylene glycol dimethacrylate, 10 g of tetramethylolmethane triacrylate, and diethylaminoethyl were added. Methacrylate 50g, toluene 40g
A mixture of 1.5 g of benzoyl peroxide and 1.5 g of benzoyl peroxide was supplied. Next, the temperature was raised to 80° C. while stirring at a stirring speed of 400 rpm, reaction was carried out for 10 hours, and the mixture was cooled. After cooling, the polymerization product was separated from the mother liquor and washed with hot water and acetone to obtain a spherical polymer having a particle size of 5 to 20 microns. The 8-12 micron particles obtained by removing fine particles and coarse particles were dispersed in 80 ml of ion-exchanged water, and the ion-exchanged water was poured into a stainless steel column (diameter 7.9 mm, length 30 cm) using a high-pressure constant flow pump. It was filled by pumping at a rate of 1.6 ml/min.
得られた充填カラムを高速液体クロマトグラフ
(商品名:島津デユポン高速液体クロマトグラフ
830型)に接続して以下の分析操作を行つた。 The resulting packed column was then processed using a high-performance liquid chromatograph (product name: Shimadzu DuPont High-Performance Liquid Chromatograph).
830 model) and performed the following analysis operations.
試料として正常人及び糖尿病患者のそれぞれの
血液50μを1c.c.のイオン交換水と混合して溶血
させたヘモグロビン溶液10μをミクロシリンジ
により注入して分析を行つた。溶離液としては
0.05Mトリス塩酸と0.01M塩化ナトリウム水溶液
との混合液をA液(PH7.8)とし、B液としてA
液にNaClを加えて0.05Mになるように調整した
水溶液を用いた。 Analysis was carried out by injecting 10 μl of a hemoglobin solution prepared by mixing 50 μl of blood from a normal person and a diabetic patient with 1 c.c. of ion-exchanged water and hemolyzing the sample using a microsyringe. As an eluent
A mixture of 0.05M Tris-HCl and 0.01M sodium chloride aqueous solution is used as Solution A (PH7.8), and A as Solution B.
An aqueous solution adjusted to 0.05M by adding NaCl to the solution was used.
A液100%で溶離を開始し、B液を2%/1分
の割合で増加させる様にした。得られたクロマト
グラムを第1図に示す。なお検出は415nmの可視
光検出機を用いた。 Elution was started with 100% solution A, and solution B was increased at a rate of 2%/1 minute. The obtained chromatogram is shown in FIG. Note that a 415 nm visible light detector was used for detection.
次に、この分野でよく知られている液体クロマ
トグラフイー用充填剤(Biorex―70、バイオラ
ツド社(米)製)を用いるイオン交換カラムクロ
マトグラフイーによつて、A1c、A0成分を約2時
間以上かけて分画し、それぞれの分画成分につい
て前記条件で本発明による高速液体クロマトグラ
フ分析を行つて、第1図のクロマトグラムのピー
ク1,2の同定を行つたところ、A1c及びA0はそ
れぞれ、2及び1のピークに一致することが分つ
た。ベースライン法で求めたHbA1cの量は正常
人血で3.5%、糖尿病患者血で6.2%であつた。 Next, the A 1 c and A 0 components were separated by ion exchange column chromatography using a liquid chromatography packing material (Biorex-70, manufactured by BioRad (USA)), which is well known in this field. Fractionation was carried out for about 2 hours or more, and high performance liquid chromatography analysis according to the present invention was performed on each fractionated component under the above conditions to identify peaks 1 and 2 in the chromatogram shown in Fig. 1. 1 c and A 0 were found to correspond to peaks 2 and 1, respectively. The amount of HbA 1 c determined by the baseline method was 3.5% in normal human blood and 6.2% in diabetic patient blood.
実施例 2
モノマーとしてノナエチレングリコールジメタ
クリレート36g、テトラメチロールメタントリア
クリレート5g及びジメチルアミノエチルメタク
リレート50gを用い、有機溶媒としてトルエン40
gを用いた以外は実施例1と同様にして充填剤及
び充填カラムを用意し、実施例1と同じ試料を用
い、同様にして分析を行つたところ、第1図と同
様なクロマトグラムが得られた。Example 2 36 g of nonaethylene glycol dimethacrylate, 5 g of tetramethylolmethane triacrylate, and 50 g of dimethylaminoethyl methacrylate were used as monomers, and 40 g of toluene was used as an organic solvent.
A packing material and a packed column were prepared in the same manner as in Example 1, except that G. It was done.
第1図は実施例1で得られた人血のクロマトグ
ラムを示す。
A……正常人血のクロマトグラム、B……糖尿
病患者血のクロマトグラム、1……HbA0のピー
ク、2……HbA1cのピーク。
FIG. 1 shows a chromatogram of human blood obtained in Example 1. A... Chromatogram of normal human blood, B... chromatogram of diabetic patient blood, 1... HbA 0 peak, 2... HbA 1 c peak.
Claims (1)
アミノ基を有する重合性モノマー(A)5〜90重量
%、分子中に2個以上の重合性2重結合を有しか
つ疎水性パラメーターが2.3以下の架橋重合性モ
ノマー(B)10〜95重量%、分子中に1個の重合性2
重結合を有し疎水性パラメーターが2.3以下にし
て上記重合性モノマー(A)とは異なるモノマー(C)0
〜85重量%からなるモノマー混合物が共重合され
てなる親水性イオン交換体を固定相とする液体ク
ロマトグラフイーによつて行われることを特徴と
する異化ヘモグロビンの分離方法。1 5 to 90% by weight of a polymerizable monomer (A) having one polymerizable double bond and one or more amino groups in the molecule, hydrophobic and having two or more polymerizable double bonds in the molecule 10 to 95% by weight of a crosslinking polymerizable monomer (B) with a property parameter of 2.3 or less, one polymerizable 2 in the molecule
A monomer (C) having a heavy bond and a hydrophobic parameter of 2.3 or less and different from the above polymerizable monomer (A)0
1. A method for separating catabolic hemoglobin, which is carried out by liquid chromatography using a hydrophilic ion exchanger as a stationary phase, which is a copolymerized monomer mixture containing ~85% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56092639A JPS57206860A (en) | 1981-06-15 | 1981-06-15 | Separation of catabolic hemoglobin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56092639A JPS57206860A (en) | 1981-06-15 | 1981-06-15 | Separation of catabolic hemoglobin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57206860A JPS57206860A (en) | 1982-12-18 |
| JPS6359464B2 true JPS6359464B2 (en) | 1988-11-18 |
Family
ID=14060013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56092639A Granted JPS57206860A (en) | 1981-06-15 | 1981-06-15 | Separation of catabolic hemoglobin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57206860A (en) |
-
1981
- 1981-06-15 JP JP56092639A patent/JPS57206860A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57206860A (en) | 1982-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4468330A (en) | Filler for liquid chromatography useful for separating a hemoglobin variant in blood | |
| Mera et al. | The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst | |
| EP0021817B1 (en) | Filler for liquid chromatography, method for separating water-soluble substances using said filler and use of said filler in separating water-soluble biochemical substances | |
| Determann | Chromatographic separations on porous gels | |
| JPH0115024B2 (en) | ||
| JP3927322B2 (en) | Method for producing packing material for liquid chromatography | |
| JPS6359464B2 (en) | ||
| JP2929456B2 (en) | Separation and quantification of glycohemoglobin | |
| US4603010A (en) | Lipoprotein fractionation | |
| CN117343240B (en) | Cation exchange polymer porous microsphere and preparation method and application thereof | |
| JP4758529B2 (en) | Packing agent for liquid chromatography and measuring method using the same | |
| JP3561350B2 (en) | Measurement method of glycated hemoglobin | |
| JPH087198B2 (en) | Quantitative method for glycated hemoglobin | |
| JPH10239301A (en) | Measurement method of glycated hemoglobin | |
| Epstein et al. | Chromatographic study of human serum by gel filtration | |
| JPS6359463B2 (en) | ||
| Schroeder | [38] Separation of peptides by chromatography on columns of Dowex 50 with volatile developers | |
| JPS60213863A (en) | Crosslinked copolymer for separation of hemoglobin | |
| CA1145737A (en) | Filling composition for use in liquid chromatography | |
| Efremov et al. | Studies on the heterogeneity of hemoglobin: XV. Separation of fetal hemoglobin and the normally occurring minor adult hemoglobins by chromatography on DEAE-cellulose | |
| JPH10227780A (en) | Method and apparatus for measuring glycated hemoglobin | |
| JPH0132945B2 (en) | ||
| Hoshino et al. | Application of high-performance liquid chromatography in establishing an accurate index of blood glucose control | |
| Jackson et al. | The resolution of urinary or serum proteins by chromatography on DEAE cellulose columns with particular reference to urinary proteins after thermal burns | |
| US5460970A (en) | Separation of acetaldehyde-induced hemoglobin (Hb A1-AcH) |